tradingkey.logo

Grail Inc

GRAL
100.070USD
+6.010+6.39%
Close 02/06, 16:00ETQuotes delayed by 15 min
3.62BMarket Cap
LossP/E TTM

Grail Inc

100.070
+6.010+6.39%

More Details of Grail Inc Company

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Grail Inc Info

Ticker SymbolGRAL
Company nameGrail Inc
IPO dateJun 12, 2024
CEORagusa (Robert)
Number of employees1000
Security typeOrdinary Share
Fiscal year-endJun 12
Address1525 O'brien Drive
CityMENLO PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94025
Phone18336942553
Websitehttps://grail.com/
Ticker SymbolGRAL
IPO dateJun 12, 2024
CEORagusa (Robert)

Company Executives of Grail Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+6082.00%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-25000.00%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.65K
+329.00%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.33K
+213.00%
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+6082.00%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-25000.00%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.65K
+329.00%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.33K
+213.00%
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
Screening
32.81M
90.64%
Development Services
3.39M
9.36%
By RegionUSD
Name
Revenue
Proportion
United States
32.65M
90.20%
International
3.55M
9.80%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Screening
32.81M
90.64%
Development Services
3.39M
9.36%

Shareholding Stats

Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
5.06%
CRCM L.P.
4.62%
Other
70.71%
Shareholders
Shareholders
Proportion
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
5.06%
CRCM L.P.
4.62%
Other
70.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
26.31%
Investment Advisor/Hedge Fund
21.22%
Hedge Fund
13.43%
Corporation
8.98%
Research Firm
4.26%
Individual Investor
1.06%
Bank and Trust
0.38%
Venture Capital
0.38%
Pension Fund
0.27%
Other
23.71%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
989
25.81M
66.22%
-6.45M
2025Q3
934
24.89M
69.05%
-6.05M
2025Q2
874
30.08M
83.61%
-1.68M
2025Q1
859
29.51M
82.19%
-2.62M
2024Q4
810
31.24M
92.16%
+4.27M
2024Q3
748
27.13M
81.56%
+4.49M
2024Q2
646
27.14M
86.18%
+27.14M
2024Q1
2
135.00
0.00%
+135.00

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Illumina Inc
3.50M
8.98%
-1.00M
-22.21%
Nov 17, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
5.45%
+37.64K
+1.81%
Sep 30, 2025
PRIMECAP Management Company
2.02M
5.18%
-33.35K
-1.62%
Sep 30, 2025
The Vanguard Group, Inc.
1.81M
4.64%
-85.37K
-4.50%
Sep 30, 2025
CRCM L.P.
1.80M
4.62%
-42.00K
-2.28%
Oct 06, 2025
Baker Bros. Advisors LP
1.63M
4.18%
--
--
Sep 30, 2025
Farallon Capital Management, L.L.C.
1.61M
4.13%
+232.00K
+16.85%
Nov 17, 2025
State Street Investment Management (US)
1.32M
3.38%
+69.55K
+5.58%
Sep 30, 2025
Arbiter Partners Capital Management, LLC
1.04M
2.66%
-2.00K
-0.19%
Sep 30, 2025
Sessa Capital
786.14K
2.02%
--
--
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ROBO Global Healthcare Technology & Innovation ETF
3.75%
Clough Select Equity ETF
2.7%
Clough Hedged Equity ETF
2.53%
Franklin Genomic Advancements ETF
2.49%
First Trust Small Cap Growth AlphaDEX Fund
1.08%
State Street SPDR S&P Biotech ETF
0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.59%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.42%
View more
ROBO Global Healthcare Technology & Innovation ETF
Proportion3.75%
Clough Select Equity ETF
Proportion2.7%
Clough Hedged Equity ETF
Proportion2.53%
Franklin Genomic Advancements ETF
Proportion2.49%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1.08%
State Street SPDR S&P Biotech ETF
Proportion0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.71%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.59%
ProShares Ultra Nasdaq Biotechnology
Proportion0.48%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.42%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI